--- a
+++ b/clusters/3009knumclusters/clust_149.txt
@@ -0,0 +1,858 @@
+Central nervous system disease
+Active central nervous system (CNS) metastases.
+Patients must not have known central nervous system metastasis or a history of central nervous system (CNS) metastases; patients with leptomeningeal disease are not eligible
+Patients must not be known to have AML in the central nervous system (CNS)
+Patients with known central nervous system (CNS) metastases are not eligible; Note: brain imaging is not an eligibility requirement
+Central nervous system (CNS) status must be determined based on a sample obtained prior to the administration of any systemic or intrathecal chemotherapy, with the exception of steroid pretreatment
+Patients with central nervous system (CNS) disease are not eligible
+Central nervous system (CNS) metastases .
+Subjects with inactive central nervous system (CNS) metastasis are eligible..
+Known central nervous system (CNS) lymphoma
+Known central nervous system (CNS) leukemia.
+Medically apparent central nervous system lymphoma or leptomeningeal disease
+Untreated or active central nervous system metastases
+AML patients with active central nervous system (CNS) disease will be excluded.
+Known untreated central nervous system metastases and/or carcinomatous meningitis
+Patients with known symptomatic central nervous system metastases requiring steroids.
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;
+Active extramedullary AML in testes or central nervous system (CNS)
+Non-central nervous system (CNS) radiotherapy within 1 week prior to C1D1 of study therapy
+Active or untreated central nervous system (CNS) metastases
+Central nervous system lymphoma or leptomeningeal infiltration
+History of central nervous system lymphoma (either primary or metastatic).
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Clinical evidence of active central nervous system leukemia;
+History or evidence of uncontrollable central nervous system (CNS) disease
+Participant must not have a known uncontrolled malignancy of the central nervous system.
+Active, untreated central nervous system (CNS) metastasis
+Subject has known current central nervous system (CNS) disease
+Symptomatic and/or untreated central nervous system metastases
+Symptomatic central nervous system metastases
+Presence of any active central nervous system (CNS) disease at the time of evaluation (parenchymal or leptomeningeal)
+Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Known active central nervous system metastases and/or carcinomatous meningitis
+Central nervous system (CNS) lymphoma or leptomeningeal infiltration
+Known central nervous system (CNS) metastases and/or carcinomatous meningitis (includes past history or current metastasis)
+Active central nervous system metastases
+Known central nervous system lymphoma.
+Central nervous system (CNS) metastases may be permitted but must be treated and neurologically stable
+History of central nervous system metastasis
+Known central nervous system (CNS) lymphoma
+Active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known central nervous system mass lesion
+Has a history of primary central nervous system malignancy.
+Participants with known untreated brain or other central nervous system metastases are excluded
+Central nervous system metastases
+Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
+Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
+Active central nervous system (CNS) disease at time of screening.
+Participants who received prior non-central nervous system (CNS) directed palliative radiation therapy within 7 days of the date of study entry
+Active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of central nervous system [CNS] metastases or spinal cord compression are eligible if they are clinically stable for at least 4 weeks before first dose of investigational product and do not require high-dose steroid treatment).
+Have known central nervous system malignancy or metastasis.
+Symptomatic central nervous system (CNS) malignancy or metastasis.
+Has a known active central nervous system metastasis and/or carcinomatous meningitis.
+History of seizure disorders or unstable central nervous system metastases
+Known active central nervous system metastases and/or carcinomatous meningitis.
+Patients with primary central nervous system (CNS) cancer.
+Active central nervous system metastases and/or carcinomatous meningitis
+Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
+Have active central nervous system (CNS) leukemia
+Any untreated central nervous system (CNS) lesion.
+Active or untreated central nervous system (CNS) metastases
+Current central nervous system (CNS) lymphoma or leptomeningeal infiltration.
+Known central nervous system (CNS) lymphoma
+Known central nervous system (CNS) lymphoma
+Central nervous system (CNS) metastases (brain or leptomeningeal)
+Symptomatic or untreated central nervous system (CNS) metastases
+Symptomatic central nervous system (CNS) metastases.
+Active central nervous system (CNS) disease.
+Patient with a tumor metastasis in the central nervous system
+Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Patients with untreated central nervous system metastases
+Known central nervous system metastases
+Known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis or known malignancy that progressed or required active treatment within the last 2 years
+Known central nervous system lymphoma
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Presence of symptomatic or untreated central nervous system (CNS) metastases
+Symptomatic and/or untreated central nervous system metastases
+Central nervous system malignancy
+Measurable disease according to RECIST v1.1 (must be outside central nervous system (CNS))
+Active central nervous system (CNS) leukemia
+Untreated central nervous system (CNS) metastases
+Have symptomatic central nervous system malignancy or metastasis.
+Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Known central nervous system (CNS) lymphoma
+Central nervous system (CNS) tumors
+Have symptomatic central nervous system (CNS) malignancy or metastasis.
+Untreated, symptomatic Central nervous system (CNS) metastases
+Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
+Central nervous system (CNS) disease
+Active extramedullary AML in testes or central nervous system (CNS)
+Symptomatic central nervous system metastasis (e.g., patients requiring increasing doses of steroids)
+Active, uncontrolled central nervous system (CNS) disease including CNS leukemia
+Uncontrolled central nervous system (CNS) metastases (previously treated with radiation and off steroids is acceptable)
+Central nervous system (CNS) metastases or seizure disorder
+Metastatic disease to the central nervous system
+Presence of central nervous system (CNS) lymphoma
+Patients with retinoblastoma protein (Rb1) positive recurrent, progressive or refractory central nervous system (CNS) tumors
+PROCUREMENT EXCLUSION CRITERIA: Patients diagnosed with primary central nervous system (CNS) tumors
+Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
+Uncontrolled metastatic disease to the brain or central nervous system (CNS).
+Patients with known central nervous system metastases, including lymphomatous meningitis
+Central nervous system metastases, including lymphomatous meningitis
+Without clinical signs of active central nervous system disease
+Known central nervous system or visceral metastases
+Have symptomatic central nervous system (CNS) malignancy (with the exception of medulloblastoma) or metastasis (screening not required).
+Presence of active untreated central nervous system (CNS) leukemia
+Presence of central nervous system (CNS) disease, which is symptomatic
+Diagnosis of primary central nervous system lymphoma
+Prior therapy for central nervous system (CNS) lymphoma\r\n* Steroids not an exclusion
+TREATMENT WITH SJCAR19: Central nervous system (CNS)-3 disease with or without neurologic changes
+EXCLUSION - PARTICIPANT: Participants with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Documented central nervous system metastases or liver metastasis
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Documented active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis;
+Patients must not have evidence of active central nervous system (CNS) disease
+Has known active (=growing) central nervous system (CNS) metastases and/or carcinomatous meningitis; radiation or resected brain metastasis are acceptable if clinically stable
+Evidence of > grade 1 central nervous system (CNS) hemorrhage on the baseline MRI scan.
+Recurrent or refractory ALL limited to isolated testicular or isolated central nervous system (CNS) disease
+Primary central nervous system malignancy
+Active central nervous system (CNS) or extramedullary disease
+Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
+Leptomeningeal carcinomatosis or other central nervous system (CNS) metastases
+Central nervous system (CNS) metastasis.
+Presence of known central nervous system (CNS) leukemia.
+Known central nervous system (CNS) lymphoma or leukemia
+Known central nervous system malignancy. Note: Central nervous system imaging is only required in subjects with suspected central nervous system malignancy.
+Active central nervous system metastases and/or leptomeningeal disease
+Known central nervous system (CNS) lymphoma
+Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable
+Has radiographically detectable central nervous system metastases and/or carcinomatous meningitis as assessed by local site investigator at the time of diagnosis
+Patients with history of prior central nervous system (CNS) metastasis must have been treated, must be asymptomatic, and must not have any of the following at the time of enrollment:
+Untreated central nervous system (CNS) metastases
+Patients with active central nervous system (CNS) leukemia eligible at the discretion of treating physician
+Symptomatic central nervous system metastases
+Uncontrolled central nervous system metastases
+Active or untreated central nervous system (CNS) metastases Exclusions Related to Cardiovascular Disease
+Patients/subjects with suspected or known central nervous system metastases unless adequately treated
+Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.
+Patients have a histologically or radiographically confirmed relapsed or refractory solid tumor or primary central nervous system (CNS) malignancy
+Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
+Subjects with symptomatic central nervous system (CNS) disease which is not adequately controlled
+Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
+Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
+Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)
+Known untreated central nervous system metastases and/or carcinomatous meningitis.
+Have central nervous system disease (CNS) as follows:
+Poorly controlled or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis
+Active central nervous system (CNS) disease
+Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
+Known primary central nervous system (CNS) malignancy
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis and/or has known active central nervous system (CNS) leukemia involvement
+Known central nervous system (CNS) metastases and/or carcinomatous meningitis
+Active, untreated central nervous system (CNS) metastases
+Patients with active visceral, central nervous system, or any bone metastases melanoma (stage IVM1b or IVM1c)
+History of central nervous system lymphoma (either primary or metastatic).
+Patients with a history of central nervous system disease must have no clinical or radiological evidence of central nervous system (CNS) disease at the time of protocol enrollment and with CNS toxicity =< grade 2; patients with seizure disorders may be enrolled if seizures are well controlled
+Presence of active and clinically relevant central nervous system (CNS) disorder;
+Presence of active and clinically relevant Central Nervous System (CNS) disorder
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Central nervous system lymphoma, including lymphomatous meningitis
+Patients with active and/or untreated central nervous system (CNS) lymphoma will not be eligible
+Patients with active, uncontrolled central nervous system (CNS) leukemia will not be eligible
+Active central nervous system (CNS) leukemia at time of treatment
+Subjects with untreated central nervous system (CNS) metastases or carcinomatous meningitis are excluded
+Presence of any significant central nervous system (CNS) or psychiatric disorder(s) that would hamper the patient's compliance;
+Patients with known brain metastases, active infection, or untreated central nervous system (CNS) leukemia
+Colorectal, hepatocellular, gallbladder, cholangiocarcinoma, neuroendocrine, melanomas, hematological and central nervous system (CNS) malignancies;
+Active central nervous system (CNS) disease in patient with history of CNS malignancy.
+Active central nervous system (CNS) or extramedullary disease unless approved by the principal investigator (PI)
+Have known central nervous system malignancy or metastasis.
+Known central nervous system (CNS) leukemia
+History of central nervous system lymphoma (either primary or metastatic).
+Patients with isolated extramedullary disease or with known parenchymal central nervous system (CNS) disease
+Patients with known active uncontrolled central nervous system (CNS) leukemia.
+Patient has known active central nervous system metastases.
+Active central nervous system (CNS) metastases.
+Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease
+Central nervous system (CNS) metastases: patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy and stable with no recurrent lesions for at least 3 months from the start of protocol therapy
+Must not have suspected or known central nervous system metastases unless adequately treated
+Subjects with symptomatic Central Nervous System (CNS) metastases
+Primary central nervous system (CNS) lymphoma
+Central nervous system (CNS) metastasis
+Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
+Has known active central nervous system (CNS) lymphoma
+Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
+Active uncontrolled central nervous system (CNS) metastases
+Participant has known history or inflammatory bowel disease, pneumonitis, or known uncontrolled metastases to the central nervous system (CNS) (with certain exceptions).
+Patients with current evidence of active central nervous system (CNS) leukemia
+Untreated or progressive central nervous system leukemia
+Active central nervous system malignancy
+Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
+Has known active central nervous system (CNS) lymphoma
+Rapidly progressive, clinically unstable central nervous system hematological malignancy. Note: Central nervous system evaluation is only required in subjects with known or suspected central nervous system malignancy.
+Known central nervous system (CNS) lymphoma
+Active, uncontrolled central nervous system (CNS) disease
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Patients with known active uncontrolled central nervous system (CNS) leukemia
+Patients with symptomatic, untreated central nervous system (CNS) metastases are not eligible
+Persons with uncontrolled central nervous system malignancy
+Patients with active central nervous system leukemia or requiring maintenance intrathecal chemotherapy
+Patients with untreated brain metastases/central nervous system (CNS) disease will be excluded
+Active central nervous system (CNS) malignancy
+Untreated central nervous system metastases; patients with a history of brain metastases must have had no central nervous system (CNS)-directed therapy within the past 60 days and radiological assessment within 30 days of study entry demonstrating a lack of progressive CNS disease
+About to undergo palliative radiation for a symptomatic central nervous system (CNS) metastasis
+Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression; subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to first dose of MEDI4736 and tremelimumab are permitted to enroll
+Eligible for extra-central nervous system (CNS) SAbR to 1-6 sites of disease
+Any history of central nervous system (CNS) metastases that is not adequately treated with surgery or SABR > 14 days prior
+Distant metastatic disease including central nervous system (CNS) or leptomeningeal metastases is not allowed
+Symptomatic and refractory central nervous system (CNS) leukemia
+Patients with central nervous system (CNS) metastases who are neurologically unstable
+Active leukemia in the central nervous system (CNS)
+Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
+Known central nervous system lymphoma
+Active central nervous system (CNS) disease in patient with history of CNS malignancy
+Central nervous system (CNS) lymphoma
+Active central nervous system malignancy
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Patient has central nervous system (CNS) metastases or seizure disorder
+Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
+Patients with clinical evidences of active central nervous system (CNS) disease at inclusion
+Active central nervous system (CNS) disease
+Patients must not have active central nervous system leukemia; patients with history of central nervous system (CNS) leukemia with no evidence of active CNS disease may be enrolled; maintenance intrathecal chemotherapy for adequately treated CNS involvement with leukemia is allowed with approval from the study supporter
+Evidence of > grade 1 central nervous system (CNS) hemorrhage or > grade 3 venous thromboembolism
+History of central nervous system disease (e.g., seizures) unrelated to cancer unless adequately controlled by medication
+Central nervous system (CNS) metastasis
+Active meningeal or central nervous system disease
+Active central nervous system metastasis and/or carcinomatous meningitis causing symptoms
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Presence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.
+Participants who have known central nervous system, meningeal, or epidural disease including brain metastases.
+Symptomatic untreated metastases in the central nervous system
+Patient with active central nervous system (CNS) disease
+Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
+AND (by central assessment) either:
+Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least 12 weeks after therapy
+Patients with carcinomatous meningitis or active central nervous system (CNS) metastases
+Active central nervous system leukemia
+Patients with a history of central nervous system disease must not have severe peripheral neuropathy, signs of leukencephalopathy, or active central nervous system (CNS) infection; patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy
+Patients may have central nervous system (CNS) metastases which have been treated and are radiographically stable for at least 4 weeks
+Known active central nervous system lymphoma
+Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed
+Patients with active central nervous system (CNS) or epidural tumor
+Active central nervous system lymphoma
+Patients with central nervous system (CNS) disease who have received treatment and disease has been stable for four weeks are eligible
+Active central nervous system (CNS) or extramedullary disease
+Evidence of central nervous system (CNS) metastases
+All patients with central nervous system lymphoma
+Active central nervous system (CNS) disease.
+Isolated extramedullary relapse (i.e. testicular, central nervous system)
+Patients with central nervous system (CNS) tumors who are receiving steroids are eligible
+Documented central nervous system metastases or liver metastasis
+Active or untreated central nervous system (CNS) metastases
+Active and/or untreated central nervous system (CNS) leukemia
+Individuals with the presence of symptomatic central nervous system (CNS) metastases requiring radiation treatment, surgery, or ongoing use of corticosteroids
+Non-central nervous system (CNS) radiotherapy within 1 week prior to C1D1 of study therapy
+Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis
+No active central nervous system (CNS) disease
+Patients with active central nervous system (CNS) disease
+Patients may NOT have evidence or symptoms of central nervous system (CNS) disease at the time of enrollment
+Clinically active central nervous system leukemia.
+Known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
+Previous radiotherapy for central nervous system metastases
+Known central nervous system (CNS) metastases requiring treatment, such as surgery, radiation or steroids
+Patients with evidence of active central nervous system lymphoma
+Known central nervous system lymphoma
+Active (symptomatic) central nervous system (CNS) metastasis.
+Known chronic or active viral infections of the central nervous system (CNS)
+Known cerebral metastases, central nervous system (CNS) or epidural tumor
+Presence of untreated and/or symptomatic central nervous system (CNS) metastasis
+Confirmed absence of central nervous system (CNS) disease
+Active central nervous system (CNS) disease
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Patients with active central nervous system (CNS) disease
+Central nervous system (CNS) metastases or seizure disorder
+Prior history of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection
+No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease
+Known central nervous system (CNS) lymphoma
+Active central nervous system (CNS) leukemia
+Known central nervous system (CNS) metastases
+Known central nervous system metastasis. Patients with history of central nervous system metastases are eligible if they are clinically or radiographically stable for at least 3 months and not taking steroids or anticonvulsants.
+Patients with active central nervous system (CNS) or epidural tumor
+Patients with known malignant disease of the central nervous system.
+History of primary central nervous system (CNS) disease that would interfere with subject evaluation
+Patient with active central nervous system (CNS) disease
+Patient has a primary central nervous system tumor
+Central nervous system (CNS) tumor refractory to intrathecal chemotherapy and/or cranio-spinal radiation
+Presence of leukemia in the central nervous system (CNS)
+No current central nervous system (CNS) myeloma at time of enrollment
+Tumors arising outside of the central nervous system (CNS)
+Active central nervous system lymphoma
+Symptomatic Central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
+Any history of disease involving the central nervous system (Part 1). Known active disease involving the central nervous system (Part 2).
+Presence of untreated or symptomatic central nervous system metastases, or central nervous system metastases that currently require local therapy (such as radiotherapy or surgery), or require doses of corticosteroids within the prior 4 weeks
+Have active central nervous system (CNS) leukemia
+Active central nervous system tumor or metastases
+Known active central nervous system or leptomeningeal lymphoma
+Presence of leukemia in the central nervous system (CNS)
+Presence of central nervous system (CNS) disease
+Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed
+Patients with active central nervous system (CNS) disease, defined as brain or meningeal metastases that are not in complete remission
+Active central nervous system malignancy
+Active central nervous system (CNS) leukemia at time of HCT
+Presence of central nervous system (CNS) metastases
+Evidence of active extramedullary disease (including central nervous system [CNS] leukemia)
+Active central nervous system (CNS) leukemia at time of HSCT
+Active central nervous system malignancy
+Patients may have active malignancy outside the central nervous system
+Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration
+Known central nervous system brain metastases
+Subject has known active central nervous system metastases and/or carcinomatous meningitis.
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Symptomatic central nervous system metastases
+Patients with central nervous system (CNS) malignancies.
+Has known active (growing) central nervous system (CNS) metastases and/or carcinomatous meningitis; prior radiation or resection is acceptable if clinically stable for at least 4 weeks
+Active, untreated central nervous system metastases.
+Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.
+Active central nervous system malignancy
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Active or history of central nervous system (CNS) metastases
+Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
+Clinically active central nervous system (CNS) leukemia;
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Symptomatic central nervous system (CNS) metastases who are neurologically unstable
+Patients with limited disease (if MF/SS: stages IA) or central nervous system (CNS) disease.
+Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma.
+History of asymptomatic or symptomatic central nervous system (CNS) metastasis
+Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
+Active central nervous system (CNS) disease in patient with history of CNS malignancy
+Known metastasis to the central nervous system
+Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
+Concommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system [CNS] therapy)
+Subjects with symptomatic, untreated metastases to the central nervous system (CNS) at the time of screening.
+Active central nervous system (CNS) disease
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known central nervous system leukemia
+Known clinically active central nervous system (CNS) leukemia
+Known clinically active central nervous system(CNS) leukemia
+Primary central nervous system (CNS) lymphoma
+Known central nervous system (CNS) lymphoma or leukemia
+Patients with known or suspected central nervous system (CNS) leukemia are not eligible
+Known active central nervous system metastases and/or carcinomatous meningitis
+Any advanced unresectable/stage IV solid tumor with exception of primary central nervous system (CNS) malignancy is permitted.
+Evidence of progressive or symptomatic central nervous system (CNS) metastases or leptomeningeal disease
+Presence of known, active central nervous system (CNS) metastases
+PRE-REGISTRATION: Primary tumors of the central nervous system.
+Central nervous system (CNS) metastases including a history of leptomeningeal carcinomatosis
+Known untreated central nervous system (CNS) metastases; leptomeningeal disease will be an absolute exclusion criterion due to limited life expectancy
+Patients should not have evidence of active central nervous system lymphoma
+History of central nervous system (CNS) metastasis.
+All patients with central nervous system lymphoma.
+Active leukemic central nervous system (CNS) disease
+Symptomatic or untreated central nervous system (CNS) metastases
+Eligible for extra-central nervous system (CNS) SABR to 1-5 sites of disease
+Any history of central nervous system (CNS) metastases that is not adequately treated (surgery or radiation) > 14 days prior to registration
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Patients with isolated extramedullary disease or with parenchymal central nervous system (CNS) disease
+Patients with known central nervous system infiltration with leukemia
+Untreated brain metastases or neurologically unstable central nervous system (CNS) metastases
+Have clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.
+Patients with symptomatic central nervous system (CNS) metastases.
+Presence of symptomatic central nervous system (CNS) metastases
+Patients with isolated central nervous system (CNS), testicular, or other extramedullary site of relapse
+Subject has known current central nervous system (CNS) disease
+Central nervous system (CNS) metastases or seizure disorder
+Pre-existing central nervous system (CNS) demyelination or seizure disorders
+Subjects must not have evidence of active leukemia in the central nervous system (CNS)
+Symptomatic central nervous system (CNS) metastases requiring treatment
+Active central nervous system (CNS) leukemia
+Central nervous system (CNS) toxicity =< grade 2
+Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
+Patients with active central nervous system (CNS) malignancy
+Symptomatic central nervous system (CNS) metastasis.
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may not participate
+Known central nervous system metastases
+Patients must not have known active central nervous system (CNS) metastases; patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy, and stable with no recurrent lesions for at least 6 months
+Distant metastatic disease including central nervous system (CNS) or leptomeningeal metastases is not allowed
+Uncontrolled central nervous system metastases
+Uncontrolled central nervous system metastases; treated, non-progressing central nervous system (CNS) disease (documented by brain magnetic resonance imaging [MRI]) off corticosteroids for at least 1 month are eligible
+Patients with known metastasis of malignant plasma cells to the central nervous system (if not suspected no specific testing is required)
+Patient has chronic or active viral infections of the central nervous system (CNS)
+Patients with disease progression in the central nervous system (CNS) only
+Patients with suspected or proven central nervous system (CNS) leukemia; (diagnostic lumbar puncture not required before enrollment)
+Patients with active central nervous system (CNS) or epidural tumor
+Lymphoma involving the central nervous system
+Patients with active central nervous system (CNS) metastases
+Known central nervous system (CNS) metastases with active symptoms, or requiring anticonvulsive medications, or steroids
+Active or suspicion of central nervous system (CNS) leukemia
+History of central nervous system (CNS) disease
+Central nervous system disease as evidence by clinical symptomatology
+Lymphoma involving the central nervous system
+Central nervous system (CNS) metastases that are symptomatic and/or requiring steroids
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Subject has clinically active central nervous system leukemia.
+Patients with known central nervous system (CNS) metastases must have stable disease off steroids after treatment with surgery or radiation therapy
+Has known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Subjects with known central nervous system disease
+Active, untreated central nervous system metastases.
+No brain or central nervous system (CNS) metastases
+Has known active central nervous system metastases and/or carcinomatous meningitis.
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Untreated or symptomatic central nervous system (CNS) metastases
+Active Central nervous system (CNS) metastases
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+known central nervous system (CNS) metastases that are untreated, symptomatic, or require steroids to control symptoms
+Known active or untreated central nervous system (CNS) metastases. - Pregnant, planning to become pregnant within 6 months of treatment, or nursing.
+Patient must have no prior history or current clinically apparent central nervous system metastases
+Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
+Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy
+Subject has symptomatic and untreated central nervous system (CNS) disease
+Known and untreated brain metastases. Patients with primary CNS (central nervous system) malignancies are excluded.
+Known central nervous system metastases or central nervous system as the only source of disease
+Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have had previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of PD 0332991
+Presence of or known history of brain/central nervous system (CNS) tumor or metastases
+Known and untreated, or active central nervous system (CNS) metastases (progressing or requiring treatment)
+Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
+Primary disease involving the Central Nervous System (CNS)
+Known active central nervous system metastases and/or carcinomatous meningitis.
+Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of central nervous system metastatic disease, have been off glucocorticoids for at least 4 weeks, have no overt evidence of neurological deficit and are ? 6 weeks from completion of brain irradiation.
+Active central nervous system disease.
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Known central nervous system metastases or central nervous system as the only source of disease
+At the time of Day 1 of the study, subjects with central nervous system (CNS) metastases must have been treated and must be asymptomatic
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
+Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement
+Known symptomatic central nervous system (CNS) metastases
+Uncontrolled central nervous system metastases
+Known history of central nervous system metastasis
+Known active central nervous system or leptomeningeal lymphoma
+Proven Central Nervous System (CNS) leukemia
+Symptomatic leukoencephalopathy, active central nervous system (CNS) malignancy or other neuropsychiatric abnormalities believed to preclude transplantation
+Has active central nervous system (CNS) or leptomeningeal metastasis
+Have symptomatic central nervous system metastasis. Screening of asymptomatic participants is not required for enrollment.
+Participant has untreated central nervous system (CNS) metastases.
+Participants with known central nervous system disease
+Has known active central nervous system metastases
+Active central nervous system metastases and/or carcinomatous meningitis
+Untreated or active/progressing Central Nervous system (CNS) metastases
+Central nervous system metastasis
+Patients are ineligible if they have any history of central nervous system (CNS) metastases
+Have symptomatic or non stable central nervous system (CNS) malignancy.
+Current or past history of central nervous system lymphoma
+History of or active central nervous system (CNS) malignancy
+Patients with primary central nervous system (CNS) lymphoma
+Known brain or central nervous system metastases or history of uncontrolled seizures.
+Has a history of known central nervous system metastasis
+Central nervous system lymphoma or leptomeningeal infiltration
+No untreated central nervous system metastases, or if treated must be neurologically stable for at least 2 weeks prior to enrollment
+Individuals with known or suspected central nervous system metastases or individuals requiring chronic daily treatment with oral corticosteroids
+Known untreated or active central nervous system (CNS) metastases
+Carcinomatous meningitis and/or symptomatic central nervous system (CNS) metastases.
+Known central nervous system lymphoma
+Active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Subject has uncontrolled metastases to the central nervous system (CNS).
+Active/symptoms of central nervous system (CNS) disease
+Patients with known active uncontrolled central nervous system (CNS) leukemia.
+Symptomatic central nervous system metastases (excluding Glioblastoma multiforrme (GBM) and Primary Central Nervous System Lymphoma (PCNSL). Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed.
+Evidence for central nervous system (CNS) metastatic disease
+Patients with active central nervous system (CNS) disease or history of brain metastases (mets) are excluded from study
+Known active central nervous system metastases and/or carcinomatous meningitis.
+Subjects with active central nervous system metastases
+Known active central nervous system lymphoma or leptomeningeal disease
+Known or suspected central nervous system metastases
+Active central nervous system (CNS) metastases requiring treatment
+Central nervous system (CNS) metastasis.
+Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
+Has radiographically detectable central nervous system (CNS) metastases and/or carcinomatous meningitis
+Symptomatic or untreated central nervous system metastases requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids; if treated, patient must be asymptomatic for 3 months prior to study entry.
+Central nervous system lymphoma or leptomeningeal infiltration
+Primary central nervous system (CNS) malignancy or active metastases within 5 years
+Have the presence of unstable central nervous system (CNS) metastasis.
+Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).
+Active or untreated central nervous system (CNS) metastasis
+Have confirmed presence of central nervous system metastases
+Known central nervous system metastases and/or carcinomatous meningitis
+Patients with untreated or symptomatic central nervous system (CNS) metastases
+Evidence of active central nervous system (CNS) leukemia
+Patient has active or history of central nervous system (CNS) disease
+Have clinical evidence or a history of central nervous system (CNS) metastasis
+Patients with known central nervous system metastases.
+Active central nervous system (CNS) metastases
+Known untreated central nervous system (CNS) metastasis
+Patients with brain metastases must have at least one site of measurable disease outside of the central nervous system
+Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
+Symptomatic Central Nervous System (CNS) metastasis
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Parts A, B, D and E: Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
+Subjects with active central nervous system (CNS) metastases are excluded
+Participants with central nervous system (CNS) lymphoma
+Untreated or symptomatic central nervous system metastases.
+Lymphoma involving the central nervous system
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Adequate central nervous system function defined as:\r\n* Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants\r\n* CNS toxicity =< grade 2
+Phase 1b: History or evidence of central nervous system (CNS) metastases
+Patients with active/uncontrolled central nervous system (CNS) leukemia
+Active central nervous system (CNS) disease at the time of treatment
+Active central nervous system (CNS) or symptomatic epidural metastatic disease
+History of central nervous system metastasis.
+Central nervous system (CNS) metastases or seizure disorder
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Symptomatic and/or untreated central nervous system metastases
+Active central nervous system metastases and/or carcinomatous meningitis
+Central nervous system metastases
+Known central nervous system lymphoma (either primary or metastatic).
+Subject has clinically active central nervous system leukemia.
+Patients with known central nervous system, meningeal, or epidural disease.
+Active central nervous system (CNS) leukemia or known CNS leukemia.
+History of central nervous system (CNS) lymphoma or other CNS disease
+Patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
+Patients with active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma
+Central nervous system (CNS) leukemia
+Central nervous system (CNS) metastasis
+Active central nervous system (CNS) metastases.
+Have clinical evidence or history of central nervous system metastasis.
+Known cytopathologically confirmed central nervous system (CNS) infiltration
+Known central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known central nervous system (CNS) lymphoma
+Current central nervous systemic disease
+Clinically apparent central nervous system metastases or carcinomatous meningitis
+Presence of known central nervous system or brain metastases
+Known central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known central nervous system metastases and/or carcinomatous meningitis.
+Known central nervous system lymphoma or leptomeningeal disease, except subjects with a history of central nervous system lymphoma treated and in remission > 6 months
+No active central nervous system (CNS) disease
+Untreated or symptomatic central nervous system (CNS) metastases
+Known active central nervous system metastases and/or carcinomatous meningitis.
+Known central nervous system metastases and/or carcinomatous meningitis
+Known central nervous system metastases and/or carcinomatous meningitis
+Known central nervous system (CNS) lymphoma
+Subjects with active cancer that has spread to the central nervous system
+Symptomatic central nervous system (CNS) malignancy or metastasis.
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known central nervous system (CNS) metastases and/or carcinomatous meningitis
+Active central nervous system metastases and/or carcinomatous meningitis
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Patients with central nervous system (CNS) tumors or known brain metastases
+Known or suspected brain or central nervous system (CNS) metastases, or carcinomatous meningitis
+Has known active central nervous system disease and/or carcinomatous meningitis
+All patients with central nervous system lymphoma
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Other serious diseases (hematological, hepatic, renal, respiratory, central nervous system, autoimmune or psychiatric)
+Any history of or current central nervous system (CNS) metastases. Baseline imaging of the brain is required within 28 days prior to randomization
+Untreated central nervous system metastatic disease l
+Prior or concurrent central nervous system (CNS) metastases
+Known central nervous system (CNS) disease
+Presence of symptomatic or uncontrolled brain or central nervous system metastases
+Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
+Central nervous system (CNS) metastases may be permitted but must be treated and neurologically stable
+Have clinical evidence or history of central nervous system metastasis
+Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
+History of central nervous system (CNS) metastasis that are untreated or not stable
+Patients with known active central nervous system (CNS) disease
+Untreated central nervous system (CNS) metastases
+Known central nervous system lymphoma
+Known central nervous system (CNS) lymphoma
+Patient has central nervous system leukemia
+Central nervous system (CNS) metastases
+Central nervous system (CNS) disease, including treated brain metastases
+Central nervous system (CNS) metastases
+Clinical evidence of active central nervous system (CNS) leukemia
+Known central nervous system lymphoma or leukemia; subjects with symptoms of CNS disease must have a negative CT scan or negative diagnostic lumbar puncture prior to randomization
+Known active or untreated central nervous system (CNS) metastases
+History of central nervous system (CNS) thrombotic/embolic or ischemic event(s)
+Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
+Known central nervous system lymphoma
+Subject has clinically active central nervous system leukemia.
+Asymptomatic, central nervous system metastases are permitted
+Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
+Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Clinical evidence of active central nervous system leukemia at the time of screening
+Phase 1: All solid tumors (measurable or evaluable disease), including primary central nervous system (CNS) tumors; exclusion of hepatoblastoma and lymphomas
+No known central nervous system (CNS) metastases
+Patients with untreated central nervous system (CNS) or epidural tumor
+Known history of central nervous system (CNS) metastases
+Any untreated central nervous system (CNS) lesion
+Symptomatic central nervous system (CNS) NHL.
+Symptomatic central nervous system (CNS) disease.
+Known central nervous system or primary mediastinal lymphoma
+Known active central nervous system (CNS) malignancy
+Previous radiotherapy for cerebral metastases, central nervous system (CNS) or epidural tumor
+Known brain metastases or primary central nervous system tumors with seizures that are not well controlled with standard medical therapy
+Presence of untreated/active central nervous system (CNS) metastases
+Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis are ineligible
+Known cytopathologically confirmed central nervous system (CNS) infiltration
+The patient has either clinically apparent central nervous system metastases or carcinomatous meningitis
+Clinically unstable central nervous system (CNS) metastasis
+Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis
+All patients with history of central nervous system lymphoma
+Clinical evidence of central nervous system (CNS) metastasis.
+Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have had previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of pazopanib
+Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment
+Patient must not have known central nervous system (CNS) leukemia
+History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis.
+Active central nervous system (CNS) leukemia
+Central nervous system metastases unless: (1) metastases have been treated and have remained controlled for at least two weeks following treatment, AND (2) patient has no residual neurological dysfunction off corticosteroids for at least one week; a CT or MRI to evaluate for central nervous system (CNS) disease is required for symptomatic patients only
+Have malignancy or metastasis of the central nervous system
+Hematologic and primary central nervous system (CNS) malignancies
+Known clinically active central nervous system (CNS) leukemia
+Any primary or active central nervous system (CNS) malignancy, including metastatic disease
+Known central nervous system leukemia/lymphoma or Richter's transformation
+Presence of leukemia in the central nervous system (CNS)
+Known active Central Nervous System (CNS) lymphoma.
+Patients with active and/or untreated central nervous system (CNS) leukemia will not be eligible
+Known central nervous system (CNS) metastases
+Known or suspected brain or other central nervous system (CNS) metastases
+Active central nervous system (CNS) metastases
+Active or prior central nervous system (CNS) leukemia, unless in complete remission for at least 3 months
+Central nervous system function defined as not severely somnolent or comatose (central cortical neurotoxicity scale < grade 3)
+Presence of central nervous system (CNS) metastatic disease
+History of demyelinating disease or inflammatory disease of the central nervous system or the peripheral nervous system
+Patients with primary central nervous system tumors or brain metastases.
+Active central nervous system (CNS) malignancy; however, patients with a history of positive Cerebrospinal fluid (CSF) cytology that has become negative with intrathecal chemotherapy are eligible.
+History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 2 months prior to first dose of study drug
+For Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasis
+Pathology from the resected brain metastasis must be consistent with a non-central nervous system primary site; Note: patients with or without active disease outside the nervous system are eligible (including patients with unknown primaries), as long as the pathology from the brain is consistent with a non-central nervous system primary site
+Active central nervous system (CNS) disease
+Patients with stable, treated central nervous system (CNS) disease are eligible
+Active central nervous system (CNS) leukemia at time of treatment
+Patients with central nervous system (CNS) metastases are eligible (as long as projected survival is > 6 months)
+Have active Central Nervous System (CNS) disease
+Primary central nervous system (CNS) lymphoma
+Has active or untreated brain or central nervous system metastases.
+Has known active central nervous system metastases and/or carcinomatous meningitis.
+History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.
+Active or history of central nervous system metastases.
+Patients with history or known presence of primary central nervous system (CNS) tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded
+Medically apparent central nervous system lymphoma or leptomeningeal disease
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Central nervous system lymphoma or leptomeningeal disease
+Subjects with symptomatic central nervous system (CNS) metastases
+Known central nervous system metastasis
+Active central nervous system (CNS) lymphoma
+Active central nervous system (CNS) leukemia
+Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)
+Patients with relapse also detected in the central nervous system (CNS) may be treated on this protocol; however, if intrathecal chemotherapy is being administered, T cells should not be administered until at least 24 hours thereafter
+Patients with brain or central nervous system metastases, including leptomeningeal disease
+Active central nervous system (CNS) disease in patient with history of CNS malignancy
+History or clinically suspicious for cancer-related Central Nervous System disease
+Patient have uncontrolled brain metastases or central nervous system disease.
+Patients may have active malignancy outside the central nervous system
+Active central nervous system metastases
+Known central nervous system lymphoma
+History or known presence of central nervous system (CNS) metastases
+Central Nervous System (CNS) disease only.
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known central nervous system malignancy.
+Active central nervous system (CNS) disease
+Active central nervous system (CNS) or extramedullary malignant disease
+Active, symptomatic central nervous system (CNS) leukemia;
+Patients with history of central nervous system (CNS) metastasis may not be enrolled on the study, unless control has been achieved with either radiation or surgical resection at least 3 months prior to enrollment on study
+Patients with known active central nervous system (CNS) leukemia
+Previous central nervous system leukemia
+Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
+Known central nervous system metastasis that is unstable within the last 2 months
+History of lymphoma involving the central nervous system
+Known central nervous system metastases
+Patients with symptomatic central nervous system (CNS) leukemia or patients with poorly controlled central nervous system leukemia
+Patients with central nervous system (CNS) disease or testicular disease are eligible
+Active, untreated central nervous system metastases.
+Active, untreated central nervous system metastases.
+Active central nervous system (CNS) leukemia
+Known active central nervous system (CNS) leukemia.
+Patients with symptomatic central nervous system (CNS) metastases
+Active central nervous system disease (CNS) metastases, as indicated by clinical symptoms, cerebral edema or progressive growth
+Known central nervous system (CNS) lymphoma
+Central nervous system (CNS) lymphoma
+Have active central nervous system (CNS) metastasis
+Known cerebral metastases, central nervous system (CNS) or epidural tumor
+Central nervous system (CNS): no recent history (within 6 month) of cerebrovascular accident, transient ischemic attacks, central nervous system or brain metastases
+Uncontrolled central nervous system (CNS) disease
+Known active central nervous system (CNS) metastases.
+Patients with known active central nervous system (CNS) leukemia will be excluded from this clinical study
+Known or suspected brain or central nervous system metastases
+Known central nervous system (CNS) disease
+Known active leukemia of the central nervous system
+All patients with active central nervous system lymphoma
+Known central nervous system metastases
+Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
+Active or untreated central nervous system (CNS) metastases
+Active or untreated central nervous system (CNS) lesions
+Symptomatic central nervous system metastases or lesions requiring treatment.
+Patients with active central nervous system (CNS) malignancy are not eligible for this trial
+Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks and the subject is neurologically stable
+Active/symptoms of central nervous system (CNS) disease
+Central nervous system (CNS) disease
+Patients with known symptomatic central nervous system (CNS) metastases requiring steroids
+Central nervous system metastasis
+Central nervous system metastases
+Untreated central nervous system (CNS) metastatic disease
+Presence of clinically apparent untreated central nervous system metastases.
+Presence of central nervous system (CNS) leukemia.
+Patients are excluded if they have a history of central nervous system (CNS) metastases
+Untreated brain or central nervous system (CNS) metastases
+Untreated central nervous system metastases
+Central nervous system (CNS) metastases or seizure disorder
+Central Nervous System (CNS) Lymphoma or chronic immunosuppression-associated central nervous system (CNS) lymphoma.
+Patients with known central nervous system metastasis are not eligible
+Active or untreated central nervous system (CNS) metastases
+Symptomatic central nervous system disease, malignancy, or metastasis
+Primary brain or other central nervous system malignancy.
+History of central nervous system hemorrhage
+Known central nervous system (CNS) or brain metastases.
+Medically apparent central nervous system lymphoma or leptomeningeal disease
+Primary central nervous system (CNS) lymphoma
+Active or untreated central nervous system (CNS) metastases
+Known central nervous system (CNS) disease, other than stable, treated brain metastases
+Active central nervous system (CNS) disease in patient with history of CNS malignancy
+Central nervous system or leptomeningeal lymphoma
+Subjects with known central nervous system (CNS) disease are not eligible, except for those subjects with treated brain metastasis.
+Known presence of central nervous system metastases
+Evidence of central nervous system metastasis
+Patients with documented central nervous system (CNS) disease
+Central nervous system metastases
+Any history or signs of central nervous system metastases;
+Known untreated central nervous system (CNS) metastasis
+Primary central nervous system (CNS) lymphoma
+Known central nervous system (CNS) disease except for treated brain metastasis
+Symptomatic and/or untreated central nervous system metastases
+Has a history of primary central nervous system malignancy.
+Evidence of central nervous system (CNS) metastasis who have not received prior definitive therapy for their lesions.
+Patient has no worsening central nervous system symptoms; and
+Symptomatic or untreated central nervous system metastases requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids; if treated, subject must be asymptomatic for 3 months prior to study entry
+Subject has clinically active central nervous system leukemia
+Untreated or active central nervous system (CNS) metastases.
+Subjects with asymptomatic brain metastases or other central nervous system (CNS) disease at screening/diagnosis are eligible
+Untreated central nervous system metastases
+Symptomatic central nervous system (CNS) metastases requiring steroid use
+Untreated/active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
+Patients with active central nervous system (CNS) disease
+Evidence of central nervous system lymphoma or lymphomatous meningitis
+Known central nervous system disease (e.g., Alzheimer's disease).
+Patients with a history of central nervous system (CNS) malignancy.
+Patients with central nervous system disease
+Current evidence of central nervous system (CNS) leukemia
+CNS (Central Nervous System) tumors as well as history of brain metastases
+Known brain tumors or Central nervous system (CNS) metastases
+Has a symptomatic central nervous system (CNS) tumor causing nausea and/or vomiting
+Patient has active or history of central nervous system (CNS) disease.
+Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors
+Patients with history or known presence of primary central nervous system (CNS) tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded
+Untreated or active brain metastases or central nervous system cancer, as defined per protocol
+History of central nervous system (CNS) PTLD
+Active central nervous system tumors or metastases
+Known active central nervous system metastases and/or carcinomatous meningitis.
+Patients with symptomatic central nervous system (CNS) metastases must have stable disease after treatment with surgery or radiation therapy
+Patients with Central Nervous System (CNS) metastasis which are: symptomatic or require treatment for symptom control and/or growing
+Radiographic evidence of central nervous system metastases that are not well controlled with local therapy (irradiation or surgery)
+Active Central Nervous System [CNS] disease
+History or presence of known central nervous system metastases
+Known central nervous system, meningeal or epidural disease including brain metastases
+Known primary central nervous system (CNS) tumors or brain metastases
+Known central nervous system (CNS) disease except for treated brain metastases
+Untreated or active cerebral nervous system metastases
+Patients with active central nervous system (CNS) lymphoma
+Symptomatic Central Nervous System (CNS) metastases
+Known untreated or active central nervous system (CNS) metastases
+Stage IV patients are considered provided they have a single non-central nervous system (CNS) metastasis (that is amenable to treatment with radiation therapy)
+Active central nervous system (CNS) disease
+Patients with active central nervous system (CNS) disease or history of brain metastases (mets) are excluded from study
+Untreated or active central nervous system (CNS) metastases
+Known central nervous system metastasis
+Subjects with known central nervous system metastases.
+Symptomatic central nervous system malignancy or metastasis (screening not required).
+Have symptomatic central nervous system (CNS) malignancy or metastasis
+Central nervous system (CNS) metastases from lymphoma or small cell lung cancer
+Primary central nervous system (CNS) malignancy or untreated/active CNS metastases
+b. Central nervous system (CNS) trauma or active seizure disorders requiring medication
+Primary malignancy of the central nervous system.
+Patients with active central nervous system (CNS) disease
+History of Central nervous system (CNS) or brain metastases
+Patients with history of central nervous system (CNS) metastasis, unless control has been achieved with either radiation or surgical resection at least 3 months prior to enrollment on study
+Uncontrolled central nervous system metastases
+No evidence of central nervous system (CNS) metastases
+Active untreated central nervous system (CNS) metastasis
+Central nervous system tumors are allowed
+Known central nervous system (CNS) lymphoma, leptomeningeal lymphoma
+Untreated central nervous system (CNS) metastases.
+Known central nervous system metastasis
+Known central nervous system lymphoma
+Active Central Nervous System (CNS) metastases or carcinomatous meningitis
+Unstable metastases to the central nervous system (CNS)
+Metastatic disease to the central nervous system
+Active MM involving the central nervous system.
+Pre-existing central nervous system (CNS) demyelination or seizure disorders
+Active MM involving the central nervous system (CNS).
+Patients with symptomatic Central Nervous System (CNS) metastases
+Active central nervous system lesions
+Active central nervous system (CNS) leukemia or known chloromatous disease
+Active central nervous system (CNS) disease (related to primary malignancy) at the time of enrollment
+Evidence of central nervous system metastasis and have not received prior definitive therapy for their lesions.
+Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases.
+Central nervous system (CNS) disease that is untreated, symptomatic, or requires therapy to control symptoms.
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Known and untreated, or active central nervous system metastases
+Participants with central nervous system (CNS) (e.g., brain or leptomeningeal) metastases.
+Has known active (= growing) central nervous system (CNS) metastases and/or carcinomatous meningitis; radiation or resected brain metastasis are acceptable if clinically stable
+Known central nervous system metastases or central nervous system as the only source of disease
+Known or suspected brain or other central nervous system metastases
+History of significant central nervous system (CNS) injury or disease predating or unrelated to cancer diagnosis
+Patient has symptomatic primary or metastatic central nervous system (CNS) disease
+Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy
+Active central nervous system (CNS) leukemia
+Patients with history of seizures or uncontrolled central nervous system (CNS) disease, significant hepatic or renal dysfunction
+Diagnosis of primary central nervous system (CNS) lymphoma
+Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy.
+Known brain metastasis or primary central nervous system (CNS) malignancy
+History of central nervous system (CNS) tumor
+Known primary central nervous system (CNS) malignancy or untreated or active CNS metastases
+Known central nervous system (CNS) lymphoma
+Cranial radiotherapy for central nervous system (CNS) leukostasis;
+History of Grade >= 2 central nervous system (CNS) hemorrhage
+Known central nervous system (CNS) lymphoma
+Presence of symptomatic central nervous system metastases.
+Uncontrolled Central Nervous System (CNS) metastases
+Subjects with untreated Central nervous system (CNS) metastases are excluded
+Have known central nervous system metastasis or Central Nervous System lymphoma;
+All patients need to have received at least one prior central nervous system (CNS) directed therapy; there is no restriction on the number of recurrences
+Participant is currently receiving treatment with benzodiazepines or other central nervous system (CNS) depressants
+Active central nervous system (CNS) disease
+Overt central nervous system manifestations of leukemia at diagnosis
+Active central nervous system (CNS) disease (the action for acupuncture may be associated with central nervous system activity, and patients with CNS pathology may respond differently to treatment than the general population)
+Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)
+Active central nervous system malignancy
+Symptomatic, untreated or unstable central nervous system or leptomeningeal metastases
+Non-central nervous system (CNS) malignant disease must be sufficiently controlled so that patient can be without additional systemic therapy for approximately 2 months
+Known metastases to the central nervous system
+Subjects with known central nervous system disease
+Subject has a history of central nervous system radiotherapy that encompasses all or part of the cochlea or will receive such radiation therapy during the course of the study.
+Has a symptomatic primary or metastatic central nervous system (CNS) malignancy with nausea and/or vomiting (asymptomatic participants may participate in study)
+Patient must not have untreated or symptomatic central nervous system (CNS) metastasis
+Central nervous system (CNS) only disease on recent imaging
+Patients with a known diagnosis of central nervous system (CNS) malignancy, including metastases, with known enhancement on magnetic resonance (MR) who are otherwise eligible to undergo MRI
+Active, untreated central nervous system metastases.
+History or current evidence of central nervous system lymphoma
+MM involving the central nervous system.
+Central nervous system (CNS) metastases
+Patients with a history of symptomatic central nervous system (CNS) unless they have been treated and are asymptomatic.
+Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
+Subject has clinically active central nervous system leukemia.
+Subject must have either radiological or established histological diagnosis of the following general categories: \r\n* High-grade glioma/central nervous system (CNS) lymphoma or \r\n* Brain metastases
+Known active or suspected central nervous system (CNS) leukemia.
+Have symptomatic central nervous system (CNS) malignancy or metastasis.
+Criteria 6, Active or untreated central nervous system (CNS) metastases per CT or MRI evaluation during screening
+Diagnosis: Must have MRI documenting a measurable lesion w/in central nervous system consistent with primary central nervous system tumor, for which maximal safe surgical resection is indicated
+Suspected central nervous system (CNS) tumor(s) or sarcoma.
+Subjects with symptomatic brain metastasis or central nervous system (CNS) disease
+History of primary central nervous system lymphoma or neoplastic central nervous system disease
+Patients with active central nervous system leukemia are excluded from this clinical trial; patients with a history of central nervous system (CNS) leukemia but no active disease at the time of enrollment are eligible; the absence of CNS disease must be confirmed by flow cytometric and cytologic examination of the cerebrospinal fluid (CSF) within 7 days of study enrollment
+Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
+Known active central nervous system (CNS) leukemia.
+Known central nervous system (CNS) lymphoma or leukemia